α-Enolase-binding peptide enhances drug delivery efficiency and therapeutic efficacy against colorectal cancer

Science Translational Medicine

Volumn 7, Issue 290, 2015, Pages

  Wu, Chien Hsun ^a,b   Kuo, Yi Huei ^b   Hong, Ruey Long ^c   Wu, Han Chung ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ENOLASE; DOXORUBICIN; NANOCARRIER; NAVELBINE; PEPTIDE DERIVATIVE; PEPTIDE PHCT74; UNCLASSIFIED DRUG; ENOLASE; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOPANNING; BIOTINYLATION; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMA CELL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TUMOR LEVEL; HCT116 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PEPTIDE LIBRARY; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TARGETING; TANDEM MASS SPECTROMETRY; AMINO ACID SEQUENCE; CHEMISTRY; COLORECTAL NEOPLASMS; DRUG SCREENING; METABOLISM; MOLECULAR GENETICS; SEQUENCE HOMOLOGY; TISSUE DISTRIBUTION; VALIDATION STUDY;

AMINO ACID SEQUENCE; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; PHOSPHOPYRUVATE HYDRATASE; SEQUENCE HOMOLOGY, AMINO ACID; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930434155     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa9391     Document Type: Article

References (43)

1. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, R. Langer, Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (2007).
2. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control. Release 65, 271-284 (2000).
3. C. Mohanty, M. Das, J. R. Kanwar, S. K. Sahoo, Receptor mediated tumor targeting: An emerging approach for cancer therapy. Curr. Drug Deliv. 8, 45-58 (2011).
4. K. C. Brown, Peptidic tumor targeting agents: The road from phage display peptide selections to clinical applications. Curr. Pharm. Des. 16, 1040-1054 (2010).
5. D. E. Lopes de Menezes, L. M. Pilarski, T. M. Allen, In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 58, 3320-3330 (1998).
6. R. M. Lu, Y. L. Chang, M. S. Chen, H. C. Wu, Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials 32, 3265-3274 (2011).
7. O. C. Farokhzad, S. Jon, A. Khademhosseini, T. N. Tran, D. A. Lavan, R. Langer, Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res. 64, 7668-7672 (2004).
8. A. Gabizon, H. Shmeeda, A. T. Horowitz, S. Zalipsky, Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Deliv. Rev. 56, 1177-1192 (2004).
9. R. J. Lee, P. S. Low, Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta 1233, 134-144 (1995).
10. T. Y. Lee, H. C. Wu, Y. L. Tseng, C. T. Lin, A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res. 64, 8002-8008 (2004).
11. A. Lo, C. T. Lin, H. C. Wu, Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol. Cancer Ther. 7, 579-589 (2008).
12. W. C. Chen, G. C. Completo, D. S. Sigal, P. R. Crocker, A. Saven, J. C. Paulson, In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood 115, 4778-4786 (2010).
13. A. I. Minchinton, I. F. Tannock, Drug penetration in solid tumours. Nat. Rev. Cancer 6, 583-592 (2006).
14. R. van der Meel, L. J. Vehmeijer, R. J. Kok, G. Storm, E. V. van Gaal, Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. Adv. Drug Deliv. Rev. 65, 1284-1298 (2013).
15. B. P. Gray, S. Li, K. C. Brown, From phage display to nanoparticle delivery: Functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker. Bioconjug. Chem. 24, 85-96 (2013).
16. B. P. Gray, K. C. Brown, Combinatorial peptide libraries: Mining for cell-binding peptides. Chem. Rev. 114, 1020-1081 (2014).
17. D. K. Chang, C. T. Lin, C. H. Wu, H. C. Wu, A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLOS One 4, e4171 (2009).
18. M. M. Taketo, W. Edelmann, Mouse models of colon cancer. Gastroenterology 136, 780-798 (2009).
19. A. Rajput, E. Agarwal, P. Leiphrakpam, M. G. Brattain, S. Chowdhury, Establishment and validation of an orthotopic metastatic mouse model of colorectal cancer. ISRN Hepatol. 2013,1-9 (2013).
20. J. A. Harding, C. M. Engbers, M. S. Newman, N. I. Goldstein, S. Zalipsky, Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim. Biophys. Acta 1327, 181-192 (1997).
21. G. A. Koning, J. A. Kamps, G. L. Scherphof, Interference of macrophages with immunotargeting of liposomes. J. Liposome Res. 12, 107-119 (2002).
22. T. A. ElBayoumi, V. P. Torchilin, Tumor-targeted nanomedicines: Enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin. Cancer Res. 15, 1973-1980 (2009).
23. R. S. Zolot, S. Basu, R. P. Million, Antibody-drug conjugates. Nat. Rev. Drug Discov. 12, 259-260 (2013).
24. B. Boyraz, M. A. Sendur, S. Aksoy, T. Babacan, E. C. Roach, M. C. Kizilarslanoglu, I. Petekkaya, K. Altundag, Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr. Med. Res. Opin. 29, 405-414 (2013).
25. A. Mullard, Maturing antibody-drug conjugate pipeline hits 30. Nat. Rev. Drug Discov. 12, 329-332 (2013).
26. M. Capello, S. Ferri-Borgogno, P. Cappello, F. Novelli, α-Enolase: A promising therapeutic and diagnostic tumor target. FEBS J. 278, 1064-1074 (2011).
27. A. Diaz-Ramos, A. Roig-Borrellas, A. Garcia-Melero, R. Lopez-Alemany, α-Enolase, a multifunctional protein: Its role on pathophysiological situations. J. Biomed. Biotechnol. 2012, 156795 (2012).
28. T. Sugahara, H. Nakajima, S. Shirahata, H. Murakami, Purification and characterization of immunoglobulin production stimulating factor-IIβ derived from Namalwa cells. Cytotechnology 10, 137-146 (1992).
29. R. A. Gatenby, R. J. Gillies, Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891-899 (2004).
30. R. G. Saldanha, M. P. Molloy, K. Bdeir, D. B. Cines, X. Song, P. M. Uitto, P. H. Weinreb, S. M. Violette, M. S. Baker, Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy. J. Proteome Res. 6, 1016-1028 (2007).
31. P. Cappello, B. Tomaino, R. Chiarle, P. Ceruti, A. Novarino, C. Castagnoli, P. Migliorini, G. Perconti, A. Giallongo, M. Milella, V. Monsurro, S. Barbi, A. Scarpa, P. Nistico, M. Giovarelli, F. Novelli, An integrated humoral and cellular response is elicited in pancreatic cancer by α-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int. J. Cancer 125, 639-648 (2009).
32. G. C. Chang, K. J. Liu, C. L. Hsieh, T. S. Hu, S. Charoenfuprasert, H. K. Liu, K. T. Luh, L. H. Hsu, C. W. Wu, C. C. Ting, C. Y. Chen, K. C. Chen, T. Y. Yang, T. Y. Chou, W. H. Wang, J. Whang-Peng, N. Y. Shih, Identification of α-enolase as an autoantigen in lung cancer: Its overexpression is associated with clinical outcomes. Clin. Cancer Res. 12, 5746-5754 (2006).
33. S. T. Tsai, I. H. Chien, W. H. Shen, Y. Z. Kuo, Y. T. Jin, T. Y. Wong, J. R. Hsiao, H. P. Wang, N. Y. Shih, L. W. Wu, ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction. Eur. J. Cancer 46, 1712-1723 (2010).
34. S. H. Tu, C. C. Chang, C. S. Chen, K. W. Tam, Y. J. Wang, C. H. Lee, H. W. Lin, T. C. Cheng, C. S. Huang, J. S. Chu, N. Y. Shih, L. C. Chen, S. J. Leu, Y. S. Ho, C. H. Wu, Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells. Breast Cancer Res. Treat. 121, 539-553 (2010).
35. T. Hamaguchi, N. Iizuka, R. Tsunedomi, Y. Hamamoto, T. Miyamoto, M. Iida, Y. Tokuhisa, K. Sakamoto, M. Takashima, T. Tamesa, M. Oka, Glycolysis module activated by hypoxia-inducible factor 1a is related to the aggressive phenotype of hepatocellular carcinoma. Int. J. Oncol. 33, 725-731 (2008).
36. M. Takashima, Y. Kuramitsu, Y. Yokoyama, N. Iizuka, M. Fujimoto, T. Nishisaka, K. Okita, M. Oka, K. Nakamura, Overexpression of α enolase in hepatitis C virus-related hepatocellular carcinoma: Association with tumor progression as determined by proteomic analysis. Proteomics 5, 1686-1692 (2005).
37. B. Tomaino, P. Cappello, M. Capello, C. Fredolini, I. Sperduti, P. Migliorini, P. Salacone, A. Novarino, A. Giacobino, L. Ciuffreda, M. Alessio, P. Nistico, A. Scarpa, P. Pederzoli, W. Zhou, E. F. Petricoin Iii, L. A. Liotta, M. Giovarelli, M. Milella, F. Novelli, Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. J. Proteome Res. 10, 105-112 (2011).
38. Y. K. Shin, B. C. Yoo, Y. S. Hong, H. J. Chang, K. H. Jung, S. Y. Jeong, J. G. Park, Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance. Electrophoresis 30,2182-2192 (2009).
39. S. Chuthapisith, R. Layfield, I. D. Kerr, C. Hughes, O. Eremin, Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int. J. Oncol. 30, 1545-1551 (2007).
40. P. Dowling, P. Meleady, A. Dowd, M. Henry, S. Glynn, M. Clynes, Proteomic analysis of isolated membrane fractions from superinvasive cancer cells. Biochim. Biophys. Acta 1774, 93-101 (2007).
41. E. Georges, A. M. Bonneau, P. Prinos, RNAi-mediated knockdown of α-enolase increases the sensitivity of tumor cells to antitubulin chemotherapeutics. Int. J. Biochem. Mol. Biol. 2, 303-308 (2011).
42. G. R. Bartlett, Phosphorus assay in column chromatography. J. Biol. Chem. 234, 466-468 (1959).
43. W. Tseng, X. Leong, E. Engleman, Orthotopic mouse model of colorectal cancer. J. Vis. Exp. e484 (2007).